Clinical trials: Inflammatory Status
Hypovitaminosis D
Cholecalciferol Supplementation for Sepsis in the ICU
Sepsis in a clinical entity that occurs in patients with serious infections. Though the severity of illness may vary, every year, approximately 1.6 million Americans are treated for sepsis.
- Trial name
- CSI (NCT01896544)
- Testing
- Cholecalciferol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Ulcerative Colitis
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared…
- Trial name
- NCT01124149
- Testing
- MMX mesalamine/ mesalazine
- Where
- 105 sites in United States, Belgium and 13 more
- Volunteers
- 759 people
- Sponsor
- Shire
Diabetes Mellitus, Type 2
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
- Trial name
- ENERGY (NCT00928889)
- Testing
- Nateglinide 120 mg, Acarbose 50 mg
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status
Ketorolac in Breast Cancer Surgery
Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.
- Conditions
- Curative Breast Cancer Surgery, Inflammatory Positive/Negative Status, Pre Surgical Incision Administration
- Trial name
- KBCt (NCT01806259)
- Testing
- Ketorolac 30 mg IV
- Where
- Belgium
- Volunteers
- 203 people
- Sponsor
- Université Catholique de Louvain